Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below: https://encyclopedia.pub/user/video_add?id=23498
Check Note
2000/2000
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 1397 2022-05-27 14:44:48 |
2 format correct Meta information modification 1397 2022-05-30 05:18:05 |
Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models
Edit
Upload a video

The formation and metabolism of IS, PCS, and IAA, from their precursors (indole for IS and IAA and p-cresol for PCS), produced by gut microbiota, to their kidney excretion through organic anion transporters (OATs) and the mechanisms that lead to their accumulation in kidney disease, have been well described in recent reviews. A number of experimental studies have explored the relationship between gut microbiota and the kidney in acute and chronic models, highlighting inter-organ crosstalk. Kidney failure is indeed responsible for the disturbance of the gut microbiota, and dysbiosis is linked to the progression of kidney failure. However, factors that may influence PBUT accumulation in the gut–kidney axis appear to be different between CKD and AKI. In CKD, external factors associated with a specific diet (low fiber intake), longterm antibiotic treatment, phosphate binder treatment, and iron supplementation, and the internal factor of high urea levels modify the gut microbiota and intestinal barrier permeability. Although AKI and CKD may share common factors, such as a specific diet or the use of antibiotics, a reduction in short-chain fatty acid levels in AKI may play a specific role in the formation of PBUTs by favoring an inflammatory state associated with intestinal barrier disruption. 

acute kidney injury uremic toxins cardiovascular dysfunction indoxyl sulfate
Information
View Times: 101
Revisions: 2 times (View History)
Update Date: 30 May 2022
Table of Contents

    1. Indoxyl Sulfate

    Indoxyl sulfate (IS) is a PBUT that strongly contributes to endothelial damage during CKD. IS is known to have many specific deleterious effects on the vascular wall, in particular, by decreasing endothelial relaxation, cell viability, and proliferation and by inducing oxidative stress [1][2][3][4]. In addition, it promotes the expression of adhesion molecules, such as ICAM-1 and MCP-1, which are associated with leukocyte extravasation, and alters endothelial permeability [5][6][7]. Moreover, it is responsible for a pro-thrombotic state by promoting tissue factor production [8][9]. A number of studies have also shown the toxicity of IS for the heart, with cardiac pro-fibrotic, pro-hypertrophic, and pro-inflammatory effects associated with the induction of oxidative stress [10][11][12][13][14][15]. However, in the specific context of AKI, its role in vascular and cardiac dysfunction is poorly understood. A number of studies have examined the vascular effects of IS in vitro using very short-term exposure, which may mimic acute exposure to IS during AKI [3][5][9]. Dou et al. exposed endothelial cells for five hours to four different concentrations of IS and showed an increase in ROS production within one hour of exposure [2]. Moreover, endothelial cells showed reduced viability and NO production after three hours of exposure to IS [4]. An increase in tissue factor and ICAM-1 expression by endothelial cells was also found after two and six hours of IS exposure, respectively [5][8]. Exposure of endothelial progenitor cells (EPCs) to IS was shown to result in a decrease in EPC viability (less proliferation and more senescence and autophagy) and the induction of oxidative stress in a dose-dependent manner. In an animal model of AKI, consisting of a unilateral ischemia-reperfusion model generated by the ligature of the left renal artery for 40 min, IS attenuated eNOs expression in the endothelium of the arteries and ischemic kidney and reduced EPC mobilization from the bone marrow [16]. More recently, two experimental studies highlighted the action of acute IS exposure on the decrease in vasorelaxation in rat aorta linked to a reduction in the release of NO [17][18]. Moreover, Savira et al. explored the role of IS in vascular and cardiac dysfunction [19][20]. They showed that IS induced cardiomyocyte hypertrophy and decreased vasorelaxation by activation of the ASK1 pathway. Furthermore, Shen et al. demonstrated the action of IS on the endothelial expression of E-selectin mediated by IL-1β in an AKI mouse model [21]. E-selectin expression was higher in kidney endothelial cells from AKI mice than in controls. In vitro, E-selectin expression was directly associated with the IS concentration in endothelial cells pre-exposed to IL-1β. These effects were associated with ROS production and higher monocyte adhesion to endothelial cells. As for E-selectin, ICAM-1 expression was induced by IS in endothelial cells pre-exposed to IL-1β in a second study [22]. The acute effect of IS on leukocyte adhesion and extravasation was also confirmed in a rat model exposed to various times of IS infusion [7]. The acute cardiac toxicity of IS was also explored in vitro [23]. The authors demonstrated a dose-dependent increase in cardiomyocyte apoptosis after 24 h of IS exposure. These results were confirmed by animal studies. Shen et al. highlighted cardiac dysfunction with pathological changes in echocardiography parameters associated with higher brain natriuretic peptide (BNP) levels and greater cardiomyocyte apoptosis in AKI mice. In addition, treatment by AST-120, an oral charcoal adsorbent that decreased IS levels, improved all parameters [22]. Furthermore, they evaluated the cardiac effect of EPC treatment in AKI mice [24]. AKI mice infused with EPC showed improved cardiac echocardiography parameters, with less cardiomyocyte apoptosis initially induced by IS and IL-1β. These results were associated with the inhibition of a pro-apoptotic protein by EPC, probably through the decrease in IS and IL-1β concentrations. These studies confirmed the direct role of IS on vascular and cardiac cell toxicity and induction of the pro-inflammatory and oxidative states during AKI. However, the association between IS, cardiovascular dysfunction, and cardiovascular complications can also be explained by the pathological action of IS on kidney disease progression. Indeed, several experimental studies have highlighted the effect of IS on the development of renal fibrosis through oxidative stress, the activation of endoplasmic reticulum stress, and the epithelial-mesenchymal transition [25][26][27][28][29][30].

    2. Para-Cresyl Sulfate

    As does IS, para-cresyl sulfate (PCS) shows toxicity towards vascular and cardiac tissues, mainly explored in CKD. It is responsible for endothelial damage, with alterations in endothelial wall permeability, microparticle release, and leukocyte recruitment [7][31][32]. It also acts on the migration and proliferation of vascular smooth muscle cells [33]. Additionally, PCS is directly involved in cardiac diastolic dysfunction by increasing cardiomyocyte apoptosis and ROS production [34]. Similar to IS, it is also responsible for cardiomyocyte hypertrophy and fibroblast collagen synthesis subsequent to the activation of ASK, a regulator of the cellular stress response [19]. P-cresol, the precursor of PCS, also has effects on the endothelium, with a decrease in cell proliferation and the disruption of adherent junctions [3][35]. Only a few experimental studies investigated the role of PCS on vascular and cardiac dysfunction during AKI. Two in vitro studies assessed the stimulatory effect of acute exposure to PCS on leukocytes, showing oxidative burst activity [36][37]. This action was associated with increased leukocyte adhesion to the vascular wall after a short-term infusion of PCS in vivo [7]. Moreover, Gross et al. demonstrated its deleterious effect on vascular reactivity in an ex vivo model of aortic rings exposed to PCS [38]. After short-term exposure to PCS (30 min), the thoracic aorta showed pathological constriction mediated by rho-kinase activation. This effect was associated with ROS production by endothelial and vascular smooth muscle cells in vitro. Moreover, PCS induced higher vascular permeability in rat vessels after 10 to 60 min of exposure at various concentrations, suggesting that PCS can induce endothelial barrier dysfunction [39]. Moreover, Huang et al. explored the effect of various concentrations of PCS on cardiomyoblasts in vitro [40]. After short-term exposure to low-level PCS, the cardiomyoblasts showed less proliferation and mitochondrial hyperfusion. This effect was considered to be a stress-induced response to acute PCS exposure. P-cresol (the gut precursor of PCS before metabolic sulfatation by the liver) was also shown to be responsible for altered cardiomyocyte contractility and the disruption of gap junctions after acute exposure [41]. However, the acute action of PCS in cardiac dysfunction needs to be evaluated in animal studies. As for IS, PCS is also responsible for the progression of renal fibrosis subsequent to the induction of oxidative stress leading to ROS production [30][42][43][44]. Thus, its action on the AKI to CKD transition should also lead to CKD-associated cardiovascular complications.

    3. Indole-3-Acetic Acid

    Indole-3-acetic acid (IAA), another PBUT, is also known to have adverse effects on vascular function during CKD. Its main role is to activate aryl hydrocarbon receptor (AhR) signaling pathways, similar to IS [8][45]. Thus, it is responsible for ROS production and pro-inflammatory molecule Cox-2 activation, as well as tissue factor production, in endothelial cells [8][46]. Three experimental studies explored the effect of very short-term exposure of endothelial cells to IAA in vitro and highlighted its pro-inflammatory and pro-apoptotic effect on endothelial cells and their progenitors [8][46][47]. However, these results need to be completed by in vivo studies. Moreover, the potential deleterious actions of IAA on the heart are still unknown. Furthermore, its contribution to the possible transition from AKI to CKD and, thus, to CKD-associated CV complications has not been specifically studied.

    References

    1. Six, I.; Gross, P.; Rémond, M.C.; Chillon, J.M.; Poirot, S.; Drueke, T.B.; Massy, Z.A. Deleterious Vascular Effects of Indoxyl Sulfate and Reversal by Oral Adsorbent AST-120. Atherosclerosis 2015, 243, 248–256.
    2. Dou, L.; Jourde-Chiche, N.; Faure, V.; Cerini, C.; Berland, Y.; Dignat-George, F.; Brunet, P. The Uremic Solute Indoxyl Sulfate Induces Oxidative Stress in Endothelial Cells. J. Thromb. Haemost. 2007, 5, 1302–1308.
    3. Dou, L.; Bertrand, E.; Cerini, C.; Faure, V.; Sampol, J.; Vanholder, R.; Berland, Y.; Brunet, P. The Uremic Solutes P-Cresol and Indoxyl Sulfate Inhibit Endothelial Proliferation and Wound Repair. Kidney Int. 2004, 65, 442–451.
    4. Tumur, Z.; Niwa, T. Indoxyl Sulfate Inhibits Nitric Oxide Production and Cell Viability by Inducing Oxidative Stress in Vascular Endothelial Cells. Am. J. Nephrol. 2009, 29, 551–557.
    5. Tumur, Z.; Shimizu, H.; Enomoto, A.; Miyazaki, H.; Niwa, T. Indoxyl Sulfate Upregulates Expression of ICAM-1 and MCP-1 by Oxidative Stress-Induced NF-KappaB Activation. Am. J. Nephrol. 2010, 31, 435–441.
    6. Maciel, R.; Cunha, R.; Busato, V.; Franco, C.; Gregório, P.; Dolenga, C.; Nakao, L.; Massy, Z.; Boullier, A.; Pecoits-Filho, R.; et al. Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. Toxins 2018, 10, 404.
    7. Pletinck, A.; Glorieux, G.; Schepers, E.; Cohen, G.; Gondouin, B.; Van Landschoot, M.; Eloot, S.; Rops, A.; Van de Voorde, J.; De Vriese, A.; et al. Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. JASN 2013, 24, 1981–1994.
    8. Gondouin, B.; Cerini, C.; Dou, L.; Sallée, M.; Duval-Sabatier, A.; Pletinck, A.; Calaf, R.; Lacroix, R.; Jourde-Chiche, N.; Poitevin, S.; et al. Indolic Uremic Solutes Increase Tissue Factor Production in Endothelial Cells by the Aryl Hydrocarbon Receptor Pathway. Kidney Int. 2013, 84, 733–744.
    9. Kamiński, T.W.; Pawlak, K.; Karbowska, M.; Myśliwiec, M.; Pawlak, D. Indoxyl Sulfate—The Uremic Toxin Linking Hemostatic System Disturbances with the Prevalence of Cardiovascular Disease in Patients with Chronic Kidney Disease. BMC Nephrol. 2017, 18, 35.
    10. Fujii, H.; Nishijima, F.; Goto, S.; Sugano, M.; Yamato, H.; Kitazawa, R.; Kitazawa, S.; Fukagawa, M. Oral Charcoal Adsorbent (AST-120) Prevents Progression of Cardiac Damage in Chronic Kidney Disease through Suppression of Oxidative Stress. Nephrol. Dial. Transplant. 2009, 24, 2089–2095.
    11. Lekawanvijit, S.; Adrahtas, A.; Kelly, D.J.; Kompa, A.R.; Wang, B.H.; Krum, H. Does Indoxyl Sulfate, a Uraemic Toxin, Have Direct Effects on Cardiac Fibroblasts and Myocytes? Eur. Heart J. 2010, 31, 1771–1779.
    12. Lekawanvijit, S.; Kumfu, S.; Wang, B.H.; Manabe, M.; Nishijima, F.; Kelly, D.J.; Krum, H.; Kompa, A.R. The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction. PLoS ONE 2013, 8, e83687.
    13. Lv, J.; Chen, J.; Wang, M.; Yan, F. Klotho Alleviates Indoxyl Sulfate-Induced Heart Failure and Kidney Damage by Promoting M2 Macrophage Polarization. Aging 2020, 12, 9139–9150.
    14. Yisireyili, M.; Shimizu, H.; Saito, S.; Enomoto, A.; Nishijima, F.; Niwa, T. Indoxyl Sulfate Promotes Cardiac Fibrosis with Enhanced Oxidative Stress in Hypertensive Rats. Life Sci. 2013, 92, 1180–1185.
    15. Lekawanvijit, S.; Krum, H. Cardiorenal Syndrome: Role of Protein-Bound Uremic Toxins. J. Ren. Nutr. 2015, 25, 149–154.
    16. Wu, V.-C.; Young, G.-H.; Huang, P.-H.; Lo, S.-C.; Wang, K.-C.; Sun, C.-Y.; Liang, C.-J.; Huang, T.-M.; Chen, J.-H.; Chang, F.-C.; et al. In Acute Kidney Injury, Indoxyl Sulfate Impairs Human Endothelial Progenitor Cells: Modulation by Statin. Angiogenesis 2013, 16, 609–624.
    17. Matsumoto, T.; Takayanagi, K.; Kojima, M.; Katome, T.; Taguchi, K.; Kobayashi, T. Direct Impairment of the Endothelial Function by Acute Indoxyl Sulfate through Declined Nitric Oxide and Not Endothelium-Derived Hyperpolarizing Factor or Vasodilator Prostaglandins in the Rat Superior Mesenteric Artery. Biol. Pharm. Bull. 2019, 42, 1236–1242.
    18. Matsumoto, T.; Takayanagi, K.; Kojima, M.; Taguchi, K.; Kobayashi, T. Acute Exposure to Indoxyl Sulfate Impairs Endothelium-Dependent Vasorelaxation in Rat Aorta. Int. J. Mol. Sci. 2019, 20, 338.
    19. Savira, F.; Cao, L.; Wang, I.; Yang, W.; Huang, K.; Hua, Y.; Jucker, B.M.; Willette, R.N.; Huang, L.; Krum, H.; et al. Apoptosis Signal-Regulating Kinase 1 Inhibition Attenuates Cardiac Hypertrophy and Cardiorenal Fibrosis Induced by Uremic Toxins: Implications for Cardiorenal Syndrome. PLoS ONE 2017, 12, e0187459.
    20. Savira, F.; Kompa, A.R.; Magaye, R.; Xiong, X.; Huang, L.; Jucker, B.M.; Willette, R.N.; Kelly, D.J.; Wang, B.H. Apoptosis Signal-Regulating Kinase 1 Inhibition Reverses Deleterious Indoxyl Sulfate-Mediated Endothelial Effects. Life Sci. 2021, 272, 119267.
    21. Shen, W.-C.; Liang, C.-J.; Huang, T.-M.; Liu, C.-W.; Wang, S.-H.; Young, G.-H.; Tsai, J.-S.; Tseng, Y.-C.; Peng, Y.-S.; Wu, V.-C.; et al. Indoxyl Sulfate Enhances IL-1β-Induced E-Selectin Expression in Endothelial Cells in Acute Kidney Injury by the ROS/MAPKs/NFκB/AP-1 Pathway. Arch. Toxicol. 2016, 90, 2779–2792.
    22. Shen, W.-C.; Chou, Y.-H.; Shi, L.-S.; Chen, Z.-W.; Tu, H.-J.; Lin, X.-Y.; Wang, G.-J. AST-120 Improves Cardiac Dysfunction in Acute Kidney Injury Mice via Suppression of Apoptosis and Proinflammatory NF-ΚB/ICAM-1 Signaling. J. Inflamm. Res. 2021, 14, 505–518.
    23. Tan, X.; Cao, X.; Zhang, P.; Xiang, F.; Teng, J.; Zou, J.; Ding, X. Endoplasmic Reticulum Stress Associated Apoptosis as a Novel Mechanism in Indoxyl Sulfate-induced Cardiomyocyte Toxicity. Mol. Med. Rep. 2018, 18, 5117–5122.
    24. Shen, W.-C.; Chou, Y.-H.; Huang, H.-P.; Sheen, J.-F.; Hung, S.-C.; Chen, H.-F. Induced Pluripotent Stem Cell-Derived Endothelial Progenitor Cells Attenuate Ischemic Acute Kidney Injury and Cardiac Dysfunction. Stem. Cell Res. Ther. 2018, 9, 344.
    25. Chen, J.-H.; Chao, C.-T.; Huang, J.-W.; Hung, K.-Y.; Liu, S.-H.; Tarng, D.-C.; Chiang, C.-K. Early Elimination of Uremic Toxin Ameliorates AKI-to-CKD Transition. Clin. Sci. 2021, 135, 2643–2658.
    26. Shu, S.; Zhu, J.; Liu, Z.; Tang, C.; Cai, J.; Dong, Z. Endoplasmic Reticulum Stress Is Activated in Post-Ischemic Kidneys to Promote Chronic Kidney Disease. EBioMedicine 2018, 37, 269–280.
    27. Saito, H.; Yoshimura, M.; Saigo, C.; Komori, M.; Nomura, Y.; Yamamoto, Y.; Sagata, M.; Wakida, A.; Chuman, E.; Nishi, K.; et al. Hepatic Sulfotransferase as a Nephropreventing Target by Suppression of the Uremic Toxin Indoxyl Sulfate Accumulation in Ischemic Acute Kidney Injury. Toxicol. Sci. 2014, 141, 206–217.
    28. Sun, C.-Y.; Chang, S.-C.; Wu, M.-S. Uremic Toxins Induce Kidney Fibrosis by Activating Intrarenal Renin–Angiotensin–Aldosterone System Associated Epithelial-to-Mesenchymal Transition. PLoS ONE 2012, 7, e34026.
    29. Shimizu, H.; Bolati, D.; Higashiyama, Y.; Nishijima, F.; Shimizu, K.; Niwa, T. Indoxyl Sulfate Upregulates Renal Expression of MCP-1 via Production of ROS and Activation of NF-ΚB, P53, ERK, and JNK in Proximal Tubular Cells. Life Sci. 2012, 90, 525–530.
    30. Lim, Y.J.; Sidor, N.A.; Tonial, N.C.; Che, A.; Urquhart, B.L. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. Toxins 2021, 13, 142.
    31. Meijers, B.K.I.; Van Kerckhoven, S.; Verbeke, K.; Dehaen, W.; Vanrenterghem, Y.; Hoylaerts, M.F.; Evenepoel, P. The Uremic Retention Solute P-Cresyl Sulfate and Markers of Endothelial Damage. Am. J. Kidney Dis. 2009, 54, 891–901.
    32. Chen, S.-C.; Huang, S.-Y.; Wu, C.-C.; Hsu, C.-F. P-Cresylsulfate, the Protein-Bound Uremic Toxin, Increased Endothelial Permeability Partly Mediated by Src-Induced Phosphorylation of VE-Cadherin. Toxins 2020, 12, 62.
    33. Han, H.; Chen, Y.; Zhu, Z.; Su, X.; Ni, J.; Du, R.; Zhang, R.; Jin, W. p-Cresyl Sulfate Promotes the Formation of Atherosclerotic Lesions and Induces Plaque Instability by Targeting Vascular Smooth Muscle Cells. Front. Med. 2016, 10, 320–329.
    34. Han, H.; Zhu, J.; Zhu, Z.; Ni, J.; Du, R.; Dai, Y.; Chen, Y.; Wu, Z.; Lu, L.; Zhang, R. p-Cresyl Sulfate Aggravates Cardiac Dysfunction Associated With Chronic Kidney Disease by Enhancing Apoptosis of Cardiomyocytes. JAHA 2015, 4, e001852.
    35. Cerini, C.; Dou, L.; Anfosso, F.; Sabatier, F.; Moal, V.; Glorieux, G.; De Smet, R.; Vanholder, R.; Dignat-George, F.; Sampol, J.; et al. P-Cresol, a Uremic Retention Solute, Alters the Endothelial Barrier Function in Vitro. Thromb. Haemost. 2004, 92, 140–150.
    36. Schepers, E.; Meert, N.; Glorieux, G.; Goeman, J.; Van der Eycken, J.; Vanholder, R. P-Cresylsulphate, the Main in Vivo Metabolite of p-Cresol, Activates Leucocyte Free Radical Production. Nephrol. Dial. Transplant. 2006, 22, 592–596.
    37. Meert, N.; Schepers, E.; Glorieux, G.; Van Landschoot, M.; Goeman, J.L.; Waterloos, M.-A.; Dhondt, A.; Van der Eycken, J.; Vanholder, R. Novel Method for Simultaneous Determination of P-Cresylsulphate and p-Cresylglucuronide: Clinical Data and Pathophysiological Implications. Nephrol. Dial. Transplant. 2012, 27, 2388–2396.
    38. Gross, P.; Massy, Z.A.; Henaut, L.; Boudot, C.; Cagnard, J.; March, C.; Kamel, S.; Drueke, T.B.; Six, I. Para-Cresyl Sulfate Acutely Impairs Vascular Reactivity and Induces Vascular Remodeling: PARA-CRESYL SULFATE AND VASCULAR DYSFUNCTION. J. Cell. Physiol. 2015, 230, 2927–2935.
    39. Tang, W.-H.; Wang, C.-P.; Yu, T.-H.; Tai, P.-Y.; Liang, S.-S.; Hung, W.-C.; Wu, C.-C.; Huang, S.-H.; Lee, Y.-J.; Chen, S.-C. Protein-Bounded Uremic Toxin p-Cresylsulfate Induces Vascular Permeability Alternations. Histochem. Cell Biol. 2018, 149, 607–617.
    40. Huang, T.-H.; Yip, H.-K.; Sun, C.-K.; Chen, Y.-L.; Yang, C.-C.; Lee, F.-Y. P-Cresyl Sulfate Causes Mitochondrial Hyperfusion in H9C2 Cardiomyoblasts. J. Cell Mol. Med. 2020, 24, 8379–8390.
    41. Peng, Y.-S.; Ding, H.-C.; Lin, Y.-T.; Syu, J.-P.; Chen, Y.; Wang, S.-M. Uremic Toxin P-Cresol Induces Disassembly of Gap Junctions of Cardiomyocytes. Toxicology 2012, 302, 11–17.
    42. Watanabe, H.; Miyamoto, Y.; Honda, D.; Tanaka, H.; Wu, Q.; Endo, M.; Noguchi, T.; Kadowaki, D.; Ishima, Y.; Kotani, S.; et al. P-Cresyl Sulfate Causes Renal Tubular Cell Damage by Inducing Oxidative Stress by Activation of NADPH Oxidase. Kidney Int. 2013, 83, 582–592.
    43. Sun, C.-Y.; Chang, S.-C.; Wu, M.-S. Suppression of Klotho Expression by Protein-Bound Uremic Toxins Is Associated with Increased DNA Methyltransferase Expression and DNA Hypermethylation. Kidney Int. 2012, 81, 640–650.
    44. Mutsaers, H.A.M.; Caetano-Pinto, P.; Seegers, A.E.M.; Dankers, A.C.A.; van den Broek, P.H.H.; Wetzels, J.F.M.; van den Brand, J.A.J.G.; van den Heuvel, L.P.; Hoenderop, J.G.; Wilmer, M.J.G.; et al. Proximal Tubular Efflux Transporters Involved in Renal Excretion of P-Cresyl Sulfate and p-Cresyl Glucuronide: Implications for Chronic Kidney Disease Pathophysiology. Toxicol. Vitr. 2015, 29, 1868–1877.
    45. Schroeder, J.C.; DiNatale, B.C.; Murray, I.A.; Flaveny, C.A.; Liu, Q.; Laurenzana, E.M.; Lin, J.M.; Strom, S.C.; Omiecinski, C.J.; Amin, S.; et al. The Uremic Toxin 3-Indoxyl Sulfate Is a Potent Endogenous Agonist for the Human Aryl Hydrocarbon Receptor. Biochemistry 2010, 49, 393–400.
    46. Dou, L.; Sallée, M.; Cerini, C.; Poitevin, S.; Gondouin, B.; Jourde-Chiche, N.; Fallague, K.; Brunet, P.; Calaf, R.; Dussol, B.; et al. The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. JASN 2015, 26, 876–887.
    47. Jourde-Chiche, N.; Dou, L.; Sabatier, F.; Calaf, R.; Cerini, C.; Robert, S.; Camoin-Jau, L.; Charpiot, P.; Argiles, A.; Dignat-George, F.; et al. Levels of Circulating Endothelial Progenitor Cells Are Related to Uremic Toxins and Vascular Injury in Hemodialysis Patients. J. Thromb. Haemost. 2009, 7, 1576–1584.
    More
    Information
    Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , ,
    View Times: 101
    Revisions: 2 times (View History)
    Update Date: 30 May 2022
    Table of Contents
      1000/1000

      Confirm

      Are you sure you want to delete?

      Video Upload Options

      Do you have a full video?
      Cite
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Titeca-Beauport, D.; Caillard, P.; Bennis, Y.; Six, I.; Bodeau, S. Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models. Encyclopedia. Available online: https://encyclopedia.pub/entry/23498 (accessed on 07 February 2023).
      Titeca-Beauport D, Caillard P, Bennis Y, Six I, Bodeau S. Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models. Encyclopedia. Available at: https://encyclopedia.pub/entry/23498. Accessed February 07, 2023.
      Titeca-Beauport, Dimitri, Pauline Caillard, Youssef Bennis, Isabelle Six, Sandra Bodeau. "Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models," Encyclopedia, https://encyclopedia.pub/entry/23498 (accessed February 07, 2023).
      Titeca-Beauport, D., Caillard, P., Bennis, Y., Six, I., & Bodeau, S. (2022, May 27). Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models. In Encyclopedia. https://encyclopedia.pub/entry/23498
      Titeca-Beauport, Dimitri, et al. ''Gut-Derived and Cardiovascular Dysfunction in Experimental AKI Models.'' Encyclopedia. Web. 27 May, 2022.
      Top
      Feedback